Effect of SGLT2 inhibitor (Lusefi) on diabetic nephropathy Stratified analysis based on different original renal function category
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000029975
- Lead Sponsor
- Fukuoka University Chikushi Hospital
- Brief Summary
There was no significant decrease in eGFR over 2 years, demonstrating renoprotective effects of luseogliflozin in patients with type 2 diabetes. Changes in eGFR were not correlated with changes in HbA1c. On the other hand, luseogliflozin had lesser renal protective effect in patients with overt proteinuria. In this study, blood sugar lowering effect, blood pressure lowering effect, liver function improving effect, and weight loss effect were also observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 53
Inclusion Criteria
Not provided
Exclusion Criteria
past use of SGLT2 inhibitor severe ketoacidosis,diabetes coma,type1diabetes severe infection,pre and post operation,severe in injury pregnancy,lactation,potential pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Renal function at 104th week post SGLT2 inhibitor treatment Stratified analysis based on different original renal function category
- Secondary Outcome Measures
Name Time Method